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SUMMARY
Fibroblast Growth Factor Receptor-1 (FGFR1) is commonly overexpressed in advanced prostate
cancer (PCa). To investigate causality, we utilized an inducible FGFR1 (iFGFR1) prostate mouse
model. Activation of iFGFR1 with chemical inducers of dimerization (CID) led to highly synchronous,
step-wise progression to adenocarcinoma that is linked to an epithelial-to-mesenchymal transition
(EMT). iFGFR1 inactivation by CID withdrawal led to full reversion of prostatic intraepithelial neopla-
sia, whereas PCa lesions became iFGFR1-independent. Gene expression profiling at distinct stages
of tumor progression revealed an increase in EMT-associated Sox9 and changes in theWnt signaling
pathway, including Fzd4, which was validated in human PCa. The iFGFR1 model clearly implicates
FGFR1 in PCa progression and demonstrates howCID-induciblemodels can help evaluate candidate
molecules in tumor progression and maintenance.INTRODUCTION
Despite improvements in prostate cancer (PCa) manage-
ment, an estimated 27,050 U.S. men will die of PCa in
2007 (Jemal et al., 2007), underscoring the need for
a more thorough molecular understanding of this resilient
disease. Significant progress has been made in the iden-
tification of molecular markers, growth factors, and other
proto-oncogenes that may be involved in PCa (Bradford
et al., 2006). In particular, members of the fibroblast
growth factor family and their receptors are known to be
highly misregulated (Kwabi-Addo et al., 2004; PowersCancet al., 2000). Although FGF receptor 1 (FGFR1) is not
normally expressed in benign prostate epithelium, it is up-
regulated in about 40% of poorly differentiated prostate
adenocarcinomas, suggestive of a causal role in disease
progression (Ozen et al., 2001; Giri et al., 1999; Naimi
et al., 2002).
FGFR1 is part of a group of growth factor receptor tyro-
sine kinases (RTK) able to induce several tumorigenic
processes, including cell proliferation, angiogenesis, inhi-
bition of apoptosis, and cell migration (Grose andDickson,
2005). RTKs have also been proposed to provide resis-
tance to cytotoxic therapies that are based on DNASIGNIFICANCE
Receptor tyrosine kinases (RTKs) can promote a range of cellular processes that can lead to tumorigenesis, mak-
ing RTKs a good therapeutic target. Development of appropriate RTK-based models that progress to prostate
cancer could facilitate elucidation of both pathological changes during progression and potential therapies.
Herein, we show that prolonged activation of inducible FGFR1 (iFGFR1) signaling is sufficient for step-wise pro-
gression to invasive PCa. This conditional, reversible model facilitated the identification of temporal differences
in responsiveness to iFGFR1 inhibition indicative of a ‘‘susceptibility window’’ for targeting FGFR1. Gene expres-
sion profiling further permitted identification of candidate molecules that can potentially differentiate FGFR1-de-
pendent and -independent stages. This model provides a platform to test single or FGFR1-combined therapies
and a proof-of-principal for similar reversible models.er Cell 12, 559–571, December 2007 ª2007 Elsevier Inc. 559
Cancer Cell
Activated FGFR1 Triggers EMT and Prostate Cancerdamage and apoptosis by inducing repair of DNA lesions
(Skorski, 2002). Another mechanism by which FGFR1 and
other RTKs are believed to induce tumorigenesis is by dis-
rupting normal epithelial/stromal communication. In the
prostate, homeostasis can be maintained, at least partly,
by paracrine signaling between stromal cells, which pro-
duce FGF7 and FGF10 and proximal epithelial cells,
expressing their cognate FGFR isoform, FGFR2iiib (Ornitz
et al., 1996). During PCa progression, alternative splicing
of FGFR2 can occur in epithelial cells, leading to isoform
changes from FGFR2iiib to the more ligand promiscuous
FGFR2iiic, along with ectopic expression of typically
stroma-localized FGFR1iiic, potentially destroying the bal-
anced interdependence between stroma and epithelium
(Carstens et al., 1997; Fenget al., 1997). Because thepros-
tate microenvironment is enriched with FGFR1 ligands
such as FGF2, changes in the FGFR axis are thought to
trigger autocrine signaling and stromal-independence
(Kwabi-Addo et al., 2004). Moreover, FGF2 is highly upre-
gulated in PCa and can support tissue remodeling via its
proangiogenic properties (Giri et al., 1999).
The development of genetically engineered mouse
(GEM) PCa models can help dissect the role of the FGF
axis in disease progression in a physiological setting. In
particular, GEM models facilitate the study of initiation
and stepwise progression of disease within the context
of the prostate microenvironment. Furthermore, perform-
ing experiments in an immunocompetent organism can
illustrate the role that stromal leukocytes can have on
disease progress, better recapitulating human disease
(Shappell et al., 2004). One of the obstacles in sorting
out the distinct roles of disparate FGF axis molecules
has been that many of the 22 known FGF ligands, 4 highly
promiscuous FGFRs, and their isoformsare typically coex-
pressed in the same tissue (Ornitz and Itoh, 2001). To over-
come this challenge, our lab developed a GEM model
based on targeted, inducible FGFR1 (iFGFR1) activation,
named the juxtaposition of CID and kinase1 (JOCK1)
model (Freeman et al., 2003). Expression of iFGFR1 was
directed to prostate epithelial cells by the use of the com-
posite probasin promoter, ARR2PB (Zhang et al., 2000).
Upon treatmentwith a synthetic, lipid-permeable chemical
inducer of dimerization (CID), prostate-localized iFGFR1
can oligomerize, leading to activation of FGFR1 signaling.
Previously, we observed that mice treated biweekly with
CID for 12–24 weeks progressed to mPIN and that early
hyperplastic changes are largely reversible after CID with-
drawal (Freeman et al., 2003).
The FGF signaling axis also plays an important role
during early stages of embryonic development, such as
gastrulation. FGFR1 is known to drive an epithelial-to-
mesenchymal transition (EMT) of primitive streak-local-
ized epiblast cells into mesoderm cells (Ciruna and
Rossant, 2001). In an EMT, epithelial cells lose their
polarity, increase their motility, and begin to express
mesenchymal markers, such as vimentin, becoming
‘‘mesenchymal-like.’’ This process has also been linked
to cancer progression, in which epithelial cells lose dif-
ferentiation markers, such as E-cadherin, and acquire560 Cancer Cell 12, 559–571, December 2007 ª2007 Elsevier Iincreased migratory capacity, leading to stromal invasion
and metastasis (Thiery, 2002). EMTs are also associated
with heterogeneous tumors with features of both carci-
nomas and sarcomas. These uncommon neoplasms
are commonly referred to as sarcomatoid carcinomas
(Thiery, 2002). In addition, the isoform switch from epith-
elial-type FGFR2IIIb to mesenchymal-type FGFR2IIIc,
along with ectopic FGFR1 expression, has been postu-
lated to be a manifestation of an EMT (Savagner et al.,
1994; Yan et al., 1993). In a 3D mammary epithelial cell
model based on mammary gland targeting, iFGFR1 was
shown to drive an EMT associated with mesenchymal
marker expression by inducing MMP3 expression and
reducing E-cadherin levels, leading to increased cell
motility (Xian et al., 2005).
Herein, we utilized the JOCK1 mouse model to test
whether prolonged FGFR1 activation could lead to PCa.
We found that after 42 weeks of CID treatment, JOCK1
mice consistently (100%) developed prostate adenocarci-
noma, which were largely sensitive to androgen ablation.
Additionally, we tested the effects of iFGFR1 inhibition
by CID withdrawal at various times during cancer progres-
sion and observed that the mPIN phenotype can com-
pletely regress to normal within 8 months. Moreover,
even relatively late withdrawal of iFGFR1 signaling can
also significantly reduce proliferation and progression of
adenocarcinoma. These results help to define a ‘‘suscepti-
bility window’’ for pharmaceutical targeting of the FGFR
axis. The use of gene expression microarrays allowed us
to identify and validate several candidate molecules that
can potentially differentiate early stages from late/nonre-
versible PCa. Finally, the development of sarcomatoid
carcinomas, composed of both spindle-shaped and epi-
thelial cells in JOCK1 mice, is strong evidence of an
iFGFR1-mediated EMT. Collectively, these results reveal
the potential roles of FGFR1 in tumor initiation, mainte-
nance, and progression at different stages of cancer pro-
gression. Thus, JOCK1mice can facilitate study of FGFR1
effects in PCa progression and are, to date, the only GEM
model based on the FGF signaling axis which displays full
penetrance to PCa.
RESULTS
Prolonged iFGFR1 Signaling Leads to Prostate
Adenocarcinoma
Prostate cancer progression in humans is divided into
several stages, progressing from preinvasive hyperplasia
and prostatic intraepithelial neoplasia (PIN) to invasive
adenocarcinoma and metastasis. Initial studies based
on the JOCK1 GEM model concluded that 12–24 weeks
of iFGFR1 signaling is sufficient to initiate PCa progression
(Freeman et al., 2003). However, invasive adenocarci-
nomawas not apparent. To determine if iFGFR1 activation
can lead to invasive adenocarcinoma or if FGFR1 signal-
ing is somehow ‘‘self-limiting,’’ JOCK1 mice were treated
biweekly for 32, 42, or 52 weeks with CID (AP20187,
2 mg/kg). Following treatment, the genitourinary (GU)
tracts, comprised of bladder, seminal vesicles, urethra,nc.
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weighed. By 42weeks of treatment, therewas a highly sig-
nificant increase in the mean GU tract size that was even
larger by week 52 relative to age-matched, JOCK-1 litter-
mates (Figures 1A and 1B). Moreover, after 52 weeks of
CID administration, some mice began to develop several
fluid-filled prostatic cysts, which may have contributed
to some of the observed changes. Thus, prolonged CID-
mediated iFGFR1 activation leads to a large increase in
prostate/GU tract size.
To determine if the increase in prostate andGU tract size
correlated with progression to PCa, we analyzed prostate
tissue sections histologically. Wild-type, untreated JOCK1
and 52-week vehicle-treated JOCK1 mice, which were
age-matched to 52-week-treated JOCK1 mice, exhibited
a normal phenotype with limited age-associated focal
hyperplasia (Figures 1C–1E). In contrast, JOCK1 mice
treated with CID for 32 weeks had predominant mPIN,
an adenocarcinoma precursor defined by nuclear atypia
along with cribiform structures and cellular tufting within
intact prostate glands. Mice also began to show signs of
invasive epithelial cells and glandular atrophy. From 42
Figure 1. Extended iFGFR1 Activation Leads to Invasive Ad-
enocarcinoma
(A) FGFR1 leads to an increase in genitourinary weight distribution of
JOCK1 CID treated mice for 42 (n = 6) and 52 weeks (n = 9) in compar-
ison to untreated (UT) wild-type (n = 6), UT JOCK1 mice (n = 9) (t test,
*p < 0.05, **p < 0.01).
(B) Macroscopic view of typical JOCK1 prostate after 52 weeks of
treatment.
(C–E) H&E analysis of age-matched wild-type (C), JOCK1 untreated
(D), and JOCK1 52 weeks (E) vehicle shows a normal ventral prostate
phenotype.
(F) JOCK1 mice treated with CID for 42–52 weeks showing areas of
invasive cancer.
(G) Higher magnification of (F) showing small invasive glands (arrow)
with hyperchromatic, atypic nuclei (arrowhead).Canweeks onward, mice developed highly synchronized and
penetrant adenocarcinoma in all lobes. These lesions
were characterized by the presence of invasive hyperchro-
matic epithelial cells with prominent nucleoli and nuclear
atypia along with the formation of multiple small invasive
glands within desmoplastic stroma (Figures 1F and 1G).
Taken together, these results show that activation of
iFGFR1 in prostate epithelial cells, and not just its ectopic
expression, leads to malignant transformation of JOCK1
prostates.
In order to better characterize the nature of JOCK1
tumors, we performed immunohistochemistry (IHC) analy-
sis. In normal prostate glands, epithelial cells are sur-
rounded by a layer of smooth muscle a-actin (SMA)
expressing cells, which is lost as glandular cells become
malignant. Mice with a normal prostate had an intact
SMA layer surrounding the glands (Figure 2A). In compar-
ison, after 32 weeks of CID treatment, JOCK-1 mice
exhibited a loss of the surrounding SMA layer (Figure 2B),
indicative of invasion.
Onecommoncharacteristic of somePCamousemodels
that express SV40 large T-antigen is the development of
tumorswith increased neuroendocrine (NE) cell character-
istics (Shappell et al., 2004). In contrast, prostate tumors
containing a large proportion of NE-like cells are rare in
humans. To determine if JOCK1 tumors are epithelial cell
derived,weexamined the expression of commonepithelial
and NE cell markers. IHC revealed cytokeratin expression
in JOCK1 tumors, indicative of invasive epithelial cells.
Furthermore, within these lesions there are regions dis-
playing a gradual loss of cytokeratin expression, suggest-
ing that thesecells have begun to lose someof their epithe-
lial characteristics (Figure 2C). Androgen receptor (AR) is
expressed primarily by secretory epithelial cells and not
normally NE cells and plays an essential role in prostate
development, cell proliferation, and inhibiting apoptosis.
In the JOCK1 model, AR staining was primarily nuclear
within invasive cells, consistent with AR activation in epi-
thelial cells (Figure 2D). In contrast, JOCK1 tumors were
negative for the NE marker synaptophysin (Figures 2E
and 2F). Finally, since growth factor receptors can activate
a variety of downstream signaling pathways, we analyzed
Akt activation by iFGFR1. Six hours after CID administra-
tion, iFGFR1 triggered Akt phosphorylation and nuclear
localization (Figures 2G and 2H). Along with reported
MAPK activation (Freeman et al., 2003), iFGFR1 can acti-
vate downstream signaling pathways that can lead to
epithelial-derived prostate tumors, indicative of invasive
adenocarcinoma and not NE carcinoma.
FGFR1 Activity Leads to Heterogeneous
Prostate Cancer
TreatedJOCK1micenotonlydevelopedwell-differentiated
adenocarcinoma, but also exhibited several distinct malig-
nant phenotypes. To quantitate and better characterize the
distributionof thesephenotypes,JOCK1 tissueswere inde-
pendently analyzed by two pathologists and the extent of
each tumor type scored from 0–3 according to proportion
of each phenotype. The most predominant phenotypescer Cell 12, 559–571, December 2007 ª2007 Elsevier Inc. 561
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ures 1F and 1G), transitional sarcomatoid-carcinoma
(TS) (Figures 3B and 3C), and frank sarcoma (Figure 3D).
Transitional sarcomatoid lesions were characterized by
a mixture of poorly differentiated epithelial cells with atyp-
ical nuclei and spindle-shaped cells around prostate car-
cinoma glands. Sarcomas present were composed of
spindle-shaped cells appearing to have formed from TS
lesions. The average scores from both pathologists were
taken and graphed according to treatment time and phe-
notype (Figure 3E). Analysis of age-matched wild-type
mice and JOCK1 control mice did not reveal any of these
four phenotypes; rather, they appeared normal. JOCK1
mice treated for 32 weeks exhibited primarily mPIN, with
Figure 2. Immunohistochemical Characterization of JOCK1
Tumors
(A and B) Wild-type mice maintain a complete smooth muscle a-actin
(red) layer surrounding prostate glands (A), while consistent with cell
invasion, JOCK1 mice lose surrounding smooth muscle layer after
32 weeks of CID (B).
(C) Expression of epithelial marker pan-cytokeratin (CK) is reduced by
invasive cells (arrow).
(D) iFGFR1 tumors display high nuclear androgen receptor in both
glandular epithelial cells and invasive cells.
(E and F) Expression of neuroendocrine marker synaptophysin in
TRAMP, but not JOCK1, tumors.
(G and H) iFGFR1 leads to an increase in Akt phosphorylation and
nuclear localization in comparison to WT mice. Insert shows nuclear
staining with DAPI pseudocolored red.562 Cancer Cell 12, 559–571, December 2007 ª2007 Elseviersome signs of PCa and TS lesions. By 42 weeks of treat-
ment, all (100%) mice developed PCa, and the extent of
adenocarcinoma increased with prolonged treatment.
Furthermore, the extent of TS lesions increased with treat-
ment, becoming frequent after 42 weeks, correlative with
PCa development. This suggests that TS lesions may be
dependent on epithelial cell invasion. Although JOCK1
mice also developed sarcomas, this was relatively rare
and the rate did not seem to increase over time, suggest-
ing that this event may require additional stochastic
cellular changes. Therefore, extended iFGFR1 activity
leads to the development of sarcomatoid carcinoma-like
tumors, suggestive of a role of FGFR1 in an epithelial-to-
mesenchymal transition in transformed epithelial cells or,
alternatively, an increase inmesenchymal cell proliferation.
FGFR1 Leads to an EMT and Distant Metastasis
The presence of atypical spindle-shaped cells surround-
ing epithelial cells led to the hypothesis that these
morphologically mesenchymal-like cells may have had
epithelial progenitors and undergone an EMT. One of the
challenges in identifying a true EMT is its transient nature.
Reduction in the levels of traditional epithelial markers as
cells become less differentiated can add to the problem
(Thiery, 2002). To test faux EMT, serial sections of iFGFR1
tumors exhibiting characteristics of both carcinomas and
sarcomas (i.e., TS tumors) were stained by H&E and IHC
for AR, E-cadherin, and cytokeratin expression (Figures
4A–4D). Mesenchymal-like cells exhibited nuclear AR ex-
pression, similar to epithelial cells (Figure 4B). Another
epithelial marker, E-cadherin, localizes to the plasma
membrane, playing awell-established role in cell adhesion.
In TS tumors, differentiated epithelial cells maintained
E-cadherin membrane localization. In contrast, invasive
morphologically mesenchymal-like cells expressed lower
and more diffuse levels of E-cadherin (Figure 4C), and a
high percentage of these mesenchymal-like cells have
loss of cytokeratin expression associated with loss of ep-
ithelial differentiation (Figure 4D). At the same time, double
IF staining showed a high percentage of these spindle-
shaped cells had high expression of the mesenchymal
marker vimentin in contrast to adjacent glandular epithelial
cells, which retained E-cadherin expression (Figure 4E).
Interestingly, we also observed a rare subset of cells
showing coexpression of E-cadherin and vimentin be-
tween epithelial and mesenchymal cells, consistent and
indicative of the transient nature of an EMT (Figure 4F).
As expected, frank sarcoma lesions displayed wide-
spread vimentin (Figure 4G) with very low cytokeratin
and E-cadherin expression (see Figure S1 in the Supple-
mental Data available with this article online) while main-
taining nuclear AR expression, suggesting that these cells
may be epithelial cell derived, and later dedifferentiated
into mesenchymal-like cells, likely by an EMT (Figure 4H).
Thus, the JOCK-1 model shows the hallmarks of an EMT
with the full spectrum of cancer progression from adeno-
carcinoma to frank sarcoma.
Previous studies have proposed a mechanism in which
FGFR1, by controlling the expression levels of theInc.
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(A–D) Prolonged iFGFR1 activation leads to adenocarcinoma and distinct phenotypes: (A) mPIN, defined by complex cribiform arrangement (*) with
papillary structures (arrow), hyperchromatic atypical nuclei, some of which have prominent nucleoli (arrowhead), and an intact smooth muscle layer
reflecting lack of invasion (SM); (B) transitional sarcomatoid-carcinoma (TS) and higher magnification (C) characterized by invasive carcinoma cells
(arrow head) surrounded by spindle-shaped cells (*); and (D) sarcomas, comprised of organized spindle-shaped cells.
(E) Shows the average pathological extent for the distribution of mPIN, adenocarcinoma, transitional sarcomatoid, and sarcoma phenotype per sam-
ple. Phenotypes were grouped and graphed according to wild-type or JOCK1 mice treatment. Results show that only age-matched wild-type mice
and JOCK1 untreated (control) mice exhibit a normal phenotype. After 42 weeks of treatment, 100% of JOCK1 mice developed adenocarcinoma.
JOCK1mice treated for 42 weeks followed by 20weeks of CIDwithdrawal show an average PCa and sarcomatoid extent higher than 42-week treated
mice, but lower than continuously treated mice. Represented as mean ± SEM.transcriptional repressor Snail, leads to an EMT during
embryonic development (Ciruna and Rossant, 2001). This
short-lived zinc finger family member is known to reduce
E-cadherin transcription levels (Zhou et al., 2004). Never-
theless, iFGFR1 did not lead to a significant increase in
Snail1mRNAinprostateepithelial cells, butSnail1/2protein
was found to be expressed in several foci in JOCK1 tumors
(Figures 4I and 4J). Thus, a combination of other factors
may be required for FGFR1 induction of Snail1 expression.
One of the properties that an EMT confers is an increase
in migratory capacity, which contributes to metastasis.
However, distant metastases were not commonly found
in tumor-bearing JOCK1 animals. Yet, despite the low fre-
quency, JOCK1 mice that developed sarcomas did show
evidence of distant metastasis by 42 weeks of CID. Spin-
dle-shaped cells were found in the liver and lymph nodes
(Figure 4K). To test if these cells were derived from pros-
tate tumors, we looked for the expression of AR and cyto-
keratins. Positive nuclear AR staining was found only in
metastatic cells but not in hepatocytes or lymphocytes.
Cytokeratin expression was also found in a subset of met-
astatic spindle-shaped cells in the liver. These metastatic
cells did not express E-cadherin, consistent with loss of
cell adhesion and increased migration. Taken together,
these results show that these spindle-shaped cells may
have had a prostate epithelial origin and subsequently
lost most of their epithelial characteristics as they became
less differentiated or more mesenchymal-like, ultimately
developing into highly malignant tumors with a propensity
for metastasis.
Deactivation of iFGFR1 Signaling by CID
Withdrawal Leads to Regression of Low-Grade
PIN and Reduces Prostate Adenocarcinoma
Progression
To determine if prolonged iFGFR1 signaling is necessary
for tumormaintenance, we took advantage of the CID sys-Cantem’s ability to terminate iFGFR1 signaling by CID with-
drawal. Previous JOCK1 studies showed that prostates
developing hyperplasia, but not those progressing to
mPIN, were able to completely regress after 8 weeks of
CID withdrawal (Freeman et al., 2003). However, we could
not rule out that an even longer period was necessary for
the regression of iFGFR1-mediated mPIN. Alternatively,
changes in prostate microenvironment, such as an in-
crease in neovascularization, could have led to iFGFR1-
independent changes or cancer progression. To address
these possibilities, iFGFR1 activity was terminated for
18–20 weeks after JOCK1 mice had been treated for 12
or 42 weeks to affect the development of mPIN or PCa, re-
spectively. Mice that developed mPIN after 12 weeks of
treatment contained glands completely filled with cells
(Figure 5A). However, by 18 weeks of CID withdrawal,
JOCK1 prostates began to show signs of reversion (n = 3)
(Figure 5B). To test if a longer CID latency period could
allow for full reversion, a larger cohort (n =7)wasexamined.
After 36weeksofdrugwithdrawal, 12-week-treatedJOCK1
mice had almost full mPIN reversion, excluding some focal
hyperplasia typical of aged mice (Figure 5C). This delay
in regression may be due to the slow reversion of neovas-
cularization seen after CID withdrawal (Winter et al., 2007).
Thus, terminating iFGFR1 activity once mPIN has devel-
oped demonstrates that FGFR1 is necessary for both
mPIN maintenance and further progression, and that even
initial neoplasticchangescan revert tonormalaftera longer
period of iFGFR1 deactivation.
In contrast to JOCK1 mice that developed mPIN,
42 week treated JOCK1 mice displaying adenocarcinoma
did not show significant signs of reversion after 20 weeks
of CID withdrawal (n = 5). These mice contained more
neoplastic prostates relative to mice treated for 42 weeks
(Figures 5D and 5E). The average pathological extent of
adenocarcinoma in mice treated for 42 weeks followed
by a 20-week CID withdrawal period was higher thancer Cell 12, 559–571, December 2007 ª2007 Elsevier Inc. 563
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(A–D) Serial sections of transitional sarcomatoid. (A) H&E staining of transitional sarcomatoid, both epithelial cells and surrounding mesenchymal-like
cells expressed nuclear AR (B). (C) Mesenchymal-like cells retained E-cadherin expression, and (D) loss of cytokeratin (CK) expression among
mesenchymal-like cells.
(E) Sarcomatoid-carcinoma lesion, with mesenchymal-like cells expressing the mesenchymal marker vimentin (green) adjacent to epithelial cells
expressing E-cadherin (red).
(F) Coexpression of vimentin (green) and E-cadherin (red) within epithelial and mesenchymal cells is indicative of a transient EMT.
(G) Sarcoma lesions express vimentin.
(H) Expression of androgen receptor by both sarcoma and glandular epithelial cells.
(I) EMT-associated Snail1 nuclear expression.
(J) iFGFR1 does not lead to a direct increase in Snail1/2 mRNA (1-way ANOVA represented as mean ± SEM).
(K) Metastatic spindle-shaped cells within the liver and lymph nodes stained by H&E and IHC for AR, Cytokeratin, and E-cadherin. Expression of
cytokeratin by metastatic mesenchymal-like cells is suggestive of sarcomatoid phenotype.JOCK1 mice treated for 42 weeks, but not as high as mice
treated continuously for 52 to 68 weeks (Figures 3E and
5F), suggesting that both iFGFR1-dependent and -inde-
pendent changes can occur after adenocarcinoma is
established. Thus, in comparison with JOCK1 mice that
progress to mPIN, inhibition of iFGFR1 does not allow
for regression of PCa but can still slow the rate of progres-
sion when compared to continuously treated JOCK1
mice. Furthermore, when mice were treated using andro-
gen ablation, there was also a difference in susceptibility
between mPIN and PCa (Figure S2). Similar to human564 Cancer Cell 12, 559–571, December 2007 ª2007 Elsevier Icancer, tumors were initially responsive to therapy, but
signs of androgen independence begin to arise in a subset
of mice with PCa.
To further address the effects of iFGFR1 signaling inhi-
bition, proliferation rates were examined by staining for
proliferation marker Ki-67 (Figures 5G–5J). Mice that
were treated for 12 weeks had about 7.5% Ki-67 positive
cells, but following CID withdrawal after 18 and 36 weeks,
the proportion of proliferating cells dropped significantly
to 2% (Figure 5K). Furthermore, there was a reduction
in the level of proliferation from JOCK1 mice treated withnc.
Cancer Cell
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ing by CID Withdrawal
(A–C) Reversibility of JOCK1mPINby 36weeks.
JOCK1 mice treated for 12 weeks with CID (A),
followed by 18 and 36 weeks of CID with-
drawal. Partial reversion of mPIN is seen after
18 weeks (B), and a complete reversion of
JOCK1 mPIN to normal prostate is seen after
36 weeks of CID withdrawal (C).
(D–F) Deactivation of iFGFR1 in mice with PCa.
(D) PCa seen after 42 weeks of CID. (E) JOCK1
prostates after 42 weeks CID treatment and 20
weeks of CIDwithdrawal. (F) JOCK1 treated for
68 weeks (F).
(G–J) Cellular proliferation measured by Ki-67
staining. JOCK1 mice treated for 12 weeks
(G), 12 weeks on/18 weeks off (H), 42 weeks
on (I), and 42 weeks on/20 weeks off (J).
(K) JOCK1 proliferating cell index shows
a reduction following CID withdrawal at both
mPIN (p < 0.001) and PCa (p = 0.0565) stages
(t test, represented as mean ± SEM).CID for 42 weeks followed by a 20-week washout period
relative to 42-week treated JOCK1mice, although the per-
centage of proliferating cells did not reach the basal levels
seen when CID was removed from 12-week treated mice
(Figure 5K). This reduction in cell proliferation could have
accounted for the slower rate of cancer progression after
drug withdrawal in comparison to JOCK1 mice treated
beyond 42 weeks. Taken together, these results show
that iFGFR1 plays a role in tumor initiation, progression,
and maintenance, and even after PCa formation, iFGFR1
deactivation reduces tumor proliferation rates. Although
difficult to quantitate, endogenous FGFR1 may partly
compensate for loss of iFGFR1 signaling, masking some
of the effects of iFGFR1 inhibition (Figure S3). These
results demonstrate that FGFR1 signaling is sufficient to
promote PCa and support the therapeutic targeting of
FGFR1 as treatment, especially at earlier stages of PCa
progression.
FGFR1 Drives Changes in Gene Expression
that Are Linked to Human PCa
In order to identify genetic changes associated with
iFGFR1-driven PCa progression, gene expression analy-
sis was performed. The ability to synchronously activate
iFGFR1 allowed us to examine gene expression changes
at distinct stages of progression, including hyperplasia,
mPIN, and PCa. This approach allowed us to determine
which genes were enriched or selected as prostates
became malignant and which genes were differentially
expressed at various stages. Candidate gene lists were
created by determining which molecules were over- or
underexpressed in 3 of 4 conditions by 2-fold or higher
with a p value and false discovery rate of less than 0.05Canin comparison to wild-type mice. The cluster heat map
of 977 misregulated genes contained several previously
identified FGFR1 target molecules, such as Mkp3/Dusp6
and Spry1, demonstrating specificity for iFGFR1 signaling
(Figure 6A; Table S1).
Reduction in FGFR2iiib expression levels has been
described for several cancers including PCa (Feng et al.,
1997; Giri et al., 1999). Reassuringly, Fgfr2 was one of
the genes found to be downregulated. In order to further
validate these results, primers that recognize exclusively
the Fgfr2iiib isoform were designed for quantitative
RT-PCR (qRT-PCR). Activation of FGFR1 for 6 and 24 hr
after CID led to a five-fold decrease in Fgfr2iiib mRNA
levels, indicating likely direct inhibition by iFGFR1 signal-
ing (Figure 6B). Previous studies have shown that while
FGFR2iiib levels are reduced in PCa progression, there
is also an increase in the FGFR2iiic isoform that accom-
panies the overexpression of FGFR1 (Carstens et al.,
1997; Feng et al., 1997). However, our results showed
that after iFGFR1 activation there is no increase in Fgfr2iiic
(data not shown), indicating that reduction of Fgfr2iiib
levels is not due to alternative splicing.
There were also differences in the expression of several
genes involved in the Wnt signaling pathway (Tables S1
and S2). Among these, the Wnt pathway receptor frizzled
4 (Fzd4), a positive modulator of canonical Wnt signaling
(Xu et al., 2004), was shown to be upregulated (Figure 6A).
Validation by qRT-PCR revealed a 2-fold increase after
24 hr and about 5-fold after 24 weeks of iFGFR1 activity
relative to wild-type animals (Figure 6C). Furthermore, the
levels of Wnt inhibitor factor-1 (Wif1), a known repressor
of Wnt signaling, began to decrease after 24 hr of FGFR1
activation (Figure 6C). The large increase in Fzd4 levelscer Cell 12, 559–571, December 2007 ª2007 Elsevier Inc. 565
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(A) Cluster heat map for the iFGFR1 gene expression profile at various stages of JOCK1 PCa progression, containing a total of 977 genes that
were over- or underexpressed in 3 of 4 conditions by 2-fold or higher, with a p value and false discovery rate of less than 0.05 in comparison to
wild-type mice.
(B) Fgfr2iiib mRNA levels measured by qRT-PCR (One-way ANOVA, p < 0.05, mean ± SEM).
(C) Validation for the expression levels of Wnt signaling members, Fzd4 and Wif1 (mean ± SEM, *p < 0.05).
(D) Expression of FZD4 in benign prostate, HG PIN, and prostate cancer. Normal tissues showed weak staining of luminal epithelial cells in more than
90%of cases. HG PIN and cancer cells hadmoderate to strong cytoplasmic staining inmore than 50%and 80%of cases, respectively. No staining of
stromal cells was seen.after 24 weeks and the continued decrease in Wif1 levels
implicate a role for the Wnt pathway in iFGFR1 tumor
progression. To further determine if iFGFR1 changes in
expression of these Wnt signaling members could help
identify novel human PCa markers, we stained human
tissue arrays for Fzd4 expression. Interestingly, both
high-grade PIN and clinically localized prostate cancers
express significantly elevated Fzd4 levels (p < 0.001 for
both groups, Mann-Whitney Rank Sum test) based on
the immunohistochemical staining scores (Figure 6D).
To determine which changes in gene expression differ-
entiate early/reversible stages from advanced/nonrevers-
ible stages of JOCK1 PCa, individual gene lists were
created after 4, 24, and 52 weeks of iFGFR1 activation.
Genes that were misregulated at each time point were
compared for molecules that overlap or differentiate the
groups (Figure 7A and Table S3). Genes found to bemisre-
gulated at late mPIN (24 weeks) and adenocarcinoma
(52 weeks) may play a role in the transition from late mPIN
to PCa. One gene found to be overexpressed at these
late stageswasosteopontin (Opn/Spp1), amolecule linked
to PCa and metastasis (Thalmann et al., 1999) (Figure 7B).566 Cancer Cell 12, 559–571, December 2007 ª2007 ElsevierFurthermore, a known OPN receptor, CD44, was also
upregulated 10-fold after 24 hr of iFGFR1 activation
(Figure 7B). Another set of genes expressed after 24 and
52 weeks was procollagen type genes: Col1a, Col8a,
Col3a1, and Col5a1 (Table S3). Collagen molecules have
been linked to a desmoplastic response in PCa, a criteria
linked to tumor invasion (Ayala et al., 2003). In order to val-
idate these results, Masson’s trichrome stain for collagen
molecules was performed. An increase in new collagen
depositionwasapparent as indicatedbyblue staining after
24 weeks of iFGFR1 activation, leading to fibrosis after 52
weeks (Figure 7C). Taken together, these results provide
a molecular gene signature for FGFR1-driven PCa pro-
gression with striking similarities with the human disease
and may help to explain the difference in reversibility at
various stages as well as indicating putative therapeutic
target.
FGFR1 Leads to an Increase
in EMT-Associated Sox9 Expression
In order to find potential molecules that could contribute
to FGFR1-mediated EMT, we focused on direct iFGFR1Inc.
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Activated FGFR1 Triggers EMT and Prostate CancerFigure 7. Comparison of Gene Expression at Distinct Stages of Tumor Progression
(A) Venn diagram from three different gene lists at various stages of iFGFR1 PCa progression: hyperplasia (4 weeks), mPIN (24 weeks), and PCa
(52 weeks).
(B) Validation of results obtained from (A) for Opn and CD44 genes. Opn was found to be overexpressed at later stages of JOCK1 PCa progression,
while one of its receptors, CD44, is a direct target of iFGFR1 signaling. Data are represented as mean ± SEM, *p < 0.05.
(C) Masson’s Trichrome stain to analyze collagen expression, which begins to increase after 24 weeks (arrow) leading to fibrosis (*).target genes that have been correlated with an EMT.
Gene expression profiling at 0, 6, and 24 hr after iFGFR1
activation (V.D.A., L.E.P., and D.M.S., unpublished data)
revealed several genes linked to EMT and tumorigenesis.
Among these, EMT-linked MMPs and TGFb signaling
axis members were found to be upregulated by FGFR1
(Thiery and Sleeman, 2006). Furthermore, the transcrip-
tion factor Sox9 was also found to be increased after
6 and 24 hr of FGFR1 activation (Figure 8A). Sox9 has
been shown to be overexpressed in recurrent human
PCa (Wang et al., 2007) and was also upregulated during
JOCK1 tumor progression (Figure 6A). Moreover, relative
to WT mice, iFGFR1-mediated PCa and sarcomas
reflected higher nuclear Sox9 staining (Figure 8B). Sox9
was also found to be expressed in both liver and lymph
node metastases (Figure 8C). Sox9 has been shown to
act synergistically with Snail1 and Snail2 to promote
EMT and to modulate both Snail1 and Snail2 expression
(Cheung et al., 2005; Sakai et al., 2006). Similar to Snail1,
Snail2/Slug is associated with EMTs and can reduce
E-cadherin levels leading to a loss of cell-cell contact
and increased migration (Bolos et al., 2003; Thiery,
2002). Snail1 and -2 were also found to be expressed
in JOCK1 metastases (Figure 8C), which were E-
cadherin-deficient. Finally, we detected the coexpression
of Sox9 and vimentin in metastatic lesions (Figure 8D).
Thus, increased expression of Sox9 by iFGFR1 in pros-
tate cells may participate in a tumorigenic EMT and
metastasis.CanDISCUSSION
It has remained controversial whether ectopic changes in
FGFR1 expression and activity are a cause or a secondary
effect of PCa progression. Previously reported prostate
GEM models, which ectopically express FGF ligands,
FGF3 or FGF8b, or constitutively active FGFR1, exhibit
cellular hyperplasia and mPIN, but not apparently invasive
adenocarcinoma (Chua et al., 2002; Wang et al., 2004;
Song et al., 2002). Interestingly, whereas Pten+/ mice
only progress to mPIN, cooperation of both FGF8b over-
expression and Pten haploinsufficiency leads to PCa after
loss of Pten heterozygosity (Zhong et al., 2006), consistent
with a role of the FGF axis in PCa. In contrast, we demon-
strate that prolonged iFGFR1 activity is sufficient to drive
initiation and step-wise progression to invasive adenocar-
cinoma with complete penetrance by 42 weeks. There are
several possible explanations for the divergent results of
previous FGFR1 models and ours. One possibility is that
the iFGFR1 allele may provide more efficient receptor olig-
omerization than so-called ‘‘constitutive’’ receptors.More-
over, the intermittent crosslinking achieved by biweekly
CID may better reflect the cyclical activation of receptors
seen in vivo that are responsive to diurnal changes in
hormones, redox levels and proinflammatory cofactors.
JOCK1 mice displayed an increase in spindle-shaped
cells, including sarcomas and lesions with features of
both carcinomas and sarcomas (known as ‘‘sarcoma-
toid-carcinomas’’), suggestive of an EMT. FGFR1 alsocer Cell 12, 559–571, December 2007 ª2007 Elsevier Inc. 567
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Activated FGFR1 Triggers EMT and Prostate CancerFigure 8. iFGFR1 Increases EMT-Associated Transcription Factor Sox9
(A) Cluster heat map of direct targets of iFGFR1 after 0, 6, and 24 hr of activation show an increase in genes that can contribute to FGFR1 tumorigenic-
EMT, such as Sox9 (arrowhead), TGFb (*) signaling, and MMP15.
(B) IHC for Sox9 shows an increase nuclear expression in iFGFR1 tumors and sarcomas in comparison to WT.
(C) High Sox9 expression in iFGFR1 metastases. Metastatic lesions also exhibited an increase in Snail1/Snail2 staining.
(D) Coexpression of Sox9 (red) and Vim (green) in lymph node metastasis.plays a crucial role in embryonic development by orches-
trating an EMT (Ciruna andRossant, 2001). In cancer, EMT
has been proposed as a mechanism for the observed
epithelial cell invasion and metastasis as cell motility is
increased. One possible molecular link between FGFR1
and an EMT is increased Sox9 levels, which is over-
expressed in recurrent PCa and can augment AR levels
(Wang et al., 2007). Sox9 also can promote both Snail
and Slug transcription and can physically interact with
Slug to promote Slug’s transcription in a feed-forward
loop (Cheung et al., 2005; Sakai et al., 2006). Additionally,
FGF2 has been shown to stimulate Sox9 expression via
the MAPK pathway (Murakami et al., 2000). Taken
together, iFGFR1 may trigger an EMT by activating the
MAPK pathway, which increases Sox9 and, in turn, Snail2,
potentiating invasion and metastasis.
What constitutes a true EMT, however, is highly conten-
tious. Cells morphologically resembling mesenchymal
cells do not always express knownmesenchymal markers
(Tarin et al., 2005) andmay revert back to epithelial cells in
a process described as a mesenchymal-to-epithelial tran-
sition. Therefore, identifying such events, especially in
vivo, may prove particularly difficult due to its transient
nature. An increase in mesenchymal cells can also occur
following prostate epithelial-targeted pRb deletion, which
leads to an expansion of fibroblast with reduced p53 levels
(Hill et al., 2005). One possibility for these stromal changes
may be the slight ‘‘off-target’’ ARR2PB promoter leaki-
ness, since the spindle-shaped cells we observe express
high levels of AR. However, when the ARR2PB promoter
was used in (‘‘EZC2-Prostate’’) reporter mice, biolumines-
cence and luciferase expression was observed almost
exclusively within prostate epithelial cells and some asso-
ciated tissues, but was orders of magnitude lower in dis-
tant organs, arguing for high specificity (Seethammagari
et al., 2006). Independently, other mouse models that
have used this promoter to target mitogenic oncogenes,568 Cancer Cell 12, 559–571, December 2007 ª2007 Elsevier Isuch as c-Myc or constitutively active caFGFR1, to the
prostate do not reveal a rapid increase in mesenchymal
cells (Ellwood-Yenet al., 2003;Wanget al., 2004). Although
paracrine signals from iFGFR1 epithelium could also lead
to mesenchymal cell proliferation, our results clearly pro-
vide evidence for an EMT event, since invasive cells retain
several epithelial markers and coexpress both epithelial
andmesenchymal markers. Also, the appearance of these
mesenchymal cells is synchronous with the development
of invasive adenocarcinoma. Thus, our results clearly sug-
gest that potent iFGFR1 signaling can lead to epithelial cell
plasticity and an EMT in PCa progression.
Due to their highly enzymatic activity, diverse functions,
and oncogenic potential, FGFR1 and other RTKs make
good targets for cancer therapy (Skorski, 2002). One
advantage of the CID system is that it can simulate
FGFR1 inhibition by drug withdrawal, indicating whether
growth factor signaling is necessary for tumor mainte-
nance. Our results show that full reversibility of mPIN is
possible by terminating iFGFR1 signaling. Thus, FGFR1
is sufficient for initiation, progression, and mPIN mainte-
nance. In contrast, PCa continued to progress indepen-
dent of iFGFR1 to a more aggressive adenocarcinoma,
albeit at a slower rate than continually treated animals.
Previous JOCK1-studies have shown that the initial hyper-
plastic changes prior to significant vascularization can be
rapidly reversible after CID withdrawal due to a quick drop
in cell proliferation and a potential increase in apoptosis
(Freeman et al., 2003). Additionally, iFGFR1 can also
promote neovascularizationby increasing theproangiogenic
factors HIF-1a, VEGF, and Ang-2 (Winter et al., 2007). How-
ever, unlike proliferation levels, maintenance of iFGFR1-
mediated neovascularization is not fully dependent on
constant signaling as shown after iFGFR1 inhibition, which
leads to a slow and gradual decrease in JOCK1 vascular-
ization. These results suggest that reductive remodeling in
vascular architecture may be a rate-limiting step in JOCK1nc.
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propose a ‘‘susceptibility window’’ for FGFR1 target
therapy, wherein patientsmay benefit most at early stages
of PCa.
Since 52-week-old untreated JOCK1 mice were virtu-
ally identical to nontransgenic mice both phenotypically
and genomically, there does not appear to be detectable
CID-independent signaling by iFGFR1. Therefore, it is
unclear how to reconcile continued PCa progression after
CID withdrawal. One possibility is that endogenous
FGFR1 could compensate for iFGFR1. Alternatively, as
prostates becomemalignant, changes in the tumor micro-
environment may establish new autocrine or paracrine
signaling from epithelial-stroma interactions, sustaining
tumor growth and vascularization. Due to differences
between early PCa stages and late/nonreversible adeno-
carcinoma for both CID withdrawal and androgen
ablation, we used gene expression microarrays to identify
candidate genes that might distinguish these stages.
Based on this approach, we observed that OPN, known
to contribute to several biological processes, including
proliferation and migration (Tuck et al., 1999; Thalmann
et al., 1999), is expressed at later PCa stages, while
OPN receptor, CD44, was rapidly induced by iFGFR1.
This result mirrors studies in other PCa mouse models,
in which OPN increases initially in mPIN and further in
adenocarcinoma (Khodavirdi et al., 2006). Thus, the
establishment of new autocrine and paracrine axes,
such as OPN/CD44, as well as changes in tumor micro-
environment found at later stages of JOCK-1 tumor pro-
gression, can help explain iFGFR1-independence.
Among other molecules identified by gene expression
profiling, we found FGFR2iiib to be downregulated.
FGFR2iiib is normally expressed by prostate epithelial
cells, and its levels tend to be reduced in PCa, while
FGFR1 (normally excluded from epithelial cells) increases
(Naimi et al., 2002; Yan et al., 1993). Reintroduction of
FGFR2 into PCa cells has been shown to reduce tumor
growth, consistent with the lack of phenotypic changes
we saw following 12-week activation of iFGFR2 (Feng
et al., 1997; Freeman et al., 2003; Matsubara et al., 1998).
Furthermore, depression of FGFR2 in the mouse prostate
accelerates mPIN progression by caFGFR1 (Jin et al.,
2003), while mice lacking Fgfr2iiib in the skin are more
prone topapillomasand squamouscell carcinomas (Grose
et al., 2007). Thus, FGFR2iiib canplaya roleasa tumorsup-
pressor, and its loss has been proposed to be a required
step in PCa progression (Carstens et al., 1997). Therefore,
FGFR1 may also promote PCa by FGFR2 inhibition.
We also observed an increase in the expression of sev-
eral Wnt axis members after iFGFR1 activation, including
Fzd4, capable of inducing b-catenin (Xu et al., 2004).
FZD4 is also significantly upregulated in human PCa and
should serve as a prognostic indicator of disease. By con-
trast, the expression of the Wnt signaling repressor, Wif1,
decreases after 4 weeks of iFGFR1 activity. Epigenetic
silencing of Wif1 in human cancer has been shown previ-
ously (Ai et al., 2006). In studies of human PCa, mRNA
levels of Wif1 were also seen to decrease, concomitantCanwith Fzd4 increase (Wissmann et al., 2003). Crosstalk
between the FGF and Wnt pathways has been widely
observed during development, such as during chick limb
development (Kawakami et al., 2001). This interplay
between FGF and Wnt has also been established for
mammary tumorigenesis, leading to a synergistic selection
in these two pathways and higher tumorigenicity (Kwan
et al., 1992; MacArthur et al., 1995; Li et al., 2000). These
results suggest that similar developmental eventsmaypro-
vide a selectiveadvantage in FGFR1-driven tumorigenesis.
In summary, we have shown that iFGFR1 signaling can
promote an EMT, invasive adenocarcinoma and metasta-
sis in an autochthonous model. Furthermore, this GEM
prostate model may facilitate determination of which sig-
naling pathways, like Wnt/b-catenin, complement FGFR1
activation.Wehave also shown that differences in sensitiv-
ity to FGFR1 inhibition at different stages of progression
are indicative of a ‘‘susceptibility window,’’ and under-
score the broad utility of CID-mediated control of signaling
molecules for optimizing treatment opportunities. Our res-
ults from gene expression profiling may prove particularly
beneficial in validating molecules that not only play a role
in the disease but complement FGFR1-independence. It
will be of particular interest to determine whether thera-
pies, such as antiangiogenesis, may complement FGFR1
inhibition and allow for reversion of prostate cancer.
EXPERIMENTAL PROCEDURES
Animals and Treatment
All mice were housed and treated at BCM’s pathogen-free Transgenic
Mouse Facility, according to regulatory standards as approved by the
Institutional Animal Care and Use Committee. Generation and geno-
typing of JOCK1 mice has been described previously (Freeman
et al., 2003). Mice were treated biweekly starting at 12 weeks of age
by intraperitoneal injections of AP20187 (Ariad Pharmaceuticals, Cam-
bridge, MA) at 2 mg/kg in drug diluent (16.7% propanediol, 22.5%
PEG400, 1.25% TWEEN 80) or drug diluent alone.
Histology and Immunohistochemistry
The genitourinary (GU) tract of mice, comprised of bladder, seminal
vesicles, urethra, and prostate lobes was removed and weighted.
The ventral, dorsal lateral, and anterior lobes of prostates were dis-
sected from the GU tract for fixing. All tissues were fixed in 10%neutral
phosphate-buffered formalin, embedded in paraffin, and cut into 5 mm
tissue sections, and hematoxylin and eosin staining was performed as
previously described (Freeman et al., 2003).
Immunohistochemistry (IHC) analysis of 5 mm sections was per-
formed by initial 55C overnight incubation of slides, deparaffinization,
and hydration. Antigen retrieval was performed using 10 mM sodium
citrate buffer for 15 min. Antibody dilutions used were anti-androgen
receptor 1:65 (Upstate, 06-680), anti-Snail 1:250 (Abcam, Ab17732),
Sox9 (1607 Santa Cruz), and anit-Ki67 1:1000 (Novacastra, United
Kingdom). For pan-cytokeratins 1:700 dilution (Dako, Z0622), antigen
retrieval was performed using proteinase K at room temperature for
15 min. Endogenous peroxidases were quenched by incubating in
3% H2O2 for 15 min. Samples were then blocked for 1 hr using 10%
goat serum followed by an overnight incubation with primary anti-
bodies. After PBS-T washing, slides were incubated with biotinylated
goat anti-rabbit (1:500) for 1 hr (1:300 for Snail). Stain was visualized
by incubating with ABC for 45 min followed by DAB for 5 min (Vector
Laboratories) and counterstain using hematoxylin.
IHC using mouse monoclonal antibodies was performed using
a M.O.M. kit (Vector Labs). Antigen retrieval was performed usingcer Cell 12, 559–571, December 2007 ª2007 Elsevier Inc. 569
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were quenched using 3% H2O2 for 15 min. Blocking endogenous
IgG receptors and subsequent steps were carried as described in
the manufacturer’s protocol.
Immunofluorescence and Double Staining
IF for SMA 1:200 (IA4, Dako) (no antigen retrieval) and p-Akt (9277S,
Cell Signaling) was performed similarly to IHC but with substitution
of ABC for streptavidin conjugated with Texas Red or FITC (Vector
Lab), and counterstained with DAPI mounting media (Vector Lab).
Double staining was performed by deparaffinizing, hydrating in
100% and 95% EtOH steps, and rinsing sections in water. 10 mM
sodium citrate antigen retrieval was performed, and endogenous IgG
receptors were blocked for 1 hr (M.O.M. kit). Sections were incubated
for 1 hr with anti-E-cadherin antibody 1:500 at 37C, washed, and
incubated for 1 hr at 37Cwith anti-mouse IgG-rhodamine-conjugated
antibody 1:100 (Santa Cruz Biotechnology, no. sc2084). Sections were
washed and blocked for 1 hr with 5% donkey sera and incubated at
4C overnight with anti-vimentin antibody (Santa Cruz, no. sc7557).
After washing steps, sections were incubated with secondary anti-
goat antibody at 1:100 (Santa Cruz, no. sc2084). Slides were counter
stained with DAPI mounting media (Vector Lab). Digital pictures were
taken using a Hamamatsu C9742-95 camera and processed using
the Simple PCI software (Complex Inc.).
Pathological Grading
Histology slides stained by H&Ewere analyzed by two pathologists (M.
Ittmann and G. Ayala) and graded from 0–3 for the extent of prostatic
intraepithelial neoplasia (PIN), adenocarcinoma, transitional sarcoma-
toid lesions, and sarcoma. The average mean and standard deviation
of both scores was taken to determine the distribution of phenotypes.
Proliferation Analysis
To determine the level of proliferation, five random high power fields of
ventral prostatewereexaminedper sample (nR5mice, except18week
off [n = 3]). The total number of Ki-67 positive cells was divided by the
total number of cells per power field, and the average of the five fields
was used to determine the average mean and standard deviation.
Analysis of Prostate Cancer Tissues
Informed consent to use tissues for research was obtained by the Baylor
ProstateCancerSPOREPathologyCoreunderan IRB-approvedprotocol.
Statistical Analysis
One-way ANOVA and one-tailed unpaired t test analysis with graphical
representation was performed using GraphPad Prism. Kruskal-Wallis
analysis of variance (ANOVA) andMann-Whitney tests were performed
to identify significant differences in central tendencies of fold ratios for
RT-PCR results.
Supplemental Experimental Procedures
Additional Experimental Procedures can be obtained in the Supple-
mental Data available with this article online.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, three supplemental figures, and three supplemental tables
and can be found with this article online at http://www.cancercell.
org/cgi/content/full/12/6/559/DC1/.
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